A fatty acid oxidation-dependent metabolic shift regulates the adaptation of BRAF-mutated melanoma to MAPK inhibitors

PURPOSE: Treatment of BRAF(V600E)-mutant melanomas with mitogen-activated protein kinase inhibitors (MAPKi) results in significant tumor regression, but acquired resistance is pervasive. To understand non-mutational mechanisms underlying the adaptation to MAPKi and to identify novel vulnerabilities...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Clin Cancer Res
Prif Awduron: Aloia, Andrea, Müllhaupt, Daniela, Chabbert, Christophe D., Eberhart, Tanja, Flückiger-Mangual, Stefanie, Vukolic, Ana, Eichhoff, Ossia, Irmisch, Anja, Alexander, Leila T., Scibona, Ernesto, Frederick, Dennie T., Miao, Benchun, Tian, Tian, Cheng, Chaoran, Kwong, Lawrence N., Wei, Zhi, Sullivan, Ryan J., Boland, Genevieve M., Herlyn, Meenhard, Flaherty, Keith T., Zamboni, Nicola, Dummer, Reinhard, Zhang, Gao, Levesque, Mitchell P., Krek, Wilhelm, Kovacs, Werner J.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2019
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6906212/
https://ncbi.nlm.nih.gov/pubmed/31375515
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-0253
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg